ARTICLE | Clinical News
Dolutegravir: Phase III started
May 18, 2015 7:00 AM UTC
ViiV began the identical, open-label, international Phase III SWORD-1 and SWORD-2 trials to compare a once-daily oral regimen of 50 mg Tivicay dolutegravir and 25 mg Edurant rilpivirine vs. continuation of current antiretroviral regimen (CAR) for 148 weeks in a total of 1,000 HIV-1-infected patients who are virologically suppressed. Patients who receive CAR will be eligible to switch to Tivicay plus Edurant. ...